SEQUENCE LISTING

```
<160> NUMBER OF SEQ ID NOS: 3

<210> SEQ ID NO 1
<211> LENGTH: 21
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> SEQUENCE: 1

cgacucacau ccuacaaaug u                                                21


<210> SEQ ID NO 2
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Rattus sp.

<400> SEQUENCE: 2

ttcagagtgt agatgacttg tttaca                                           26


<210> SEQ ID NO 3
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 3

ttttggagtg taggtgactt gtttact                                          27
```

1-34. (canceled)

35. A method of assessing whether a kidney disease (KD) patient is responsive to treatment with a therapeutic, the method comprising detecting the amount of vesicles or their luminal contents in a test urine sample obtained from a KD patient treated with the therapeutic, as compared to or relative to the amount of vesicles or their luminal contents in a control urine sample, wherein a higher or lower amount of vesicles or their luminal contents in the test urine sample as compared to the amount of vesicles or their luminal contents in the control urine sample is indicative of the patient's responsiveness to treatment with the therapeutic.

36. The method of claim **35**, wherein the therapeutic comprises an enriched population of renal cells.

37. The method of claim **36**, wherein the enriched population of renal cells is enriched for renal tubular cells.

38. The method of claim **37**, where the enriched population of renal cell cells further comprises epithelial cells of the collecting duct system.

39. The method of claim **35**, wherein the vesicles comprise a biomarker.

40. The method of claim **39**, wherein the biomarker is miRNA.

41. The method of claim **40**, wherein the miRNA comprises one or more of miR-370, miR-362, miR-1224, miR-22, miR-598-5p, miR-540, miR-300-3p, miR-206, miR-222, miR-433, let-7b, let-7c, miR-497, let-7b*, miR-24-2*, miR-770, miR-124, miR-485, miR-760-5p, miR-296, miR-764, miR-221, miR-883, miR-15b, miR-143, let-7a, miR-339-3p, miR-484, miR-742, miR-101b, miR-425, miR-31, miR-29b, let-7e*, miR-345-3p, miR-193, miR-207, miR-501, miR-125b-3p, miR-154, miR-375, miR-298, miR-671, miR-21, let-7e, let-7f, miR-125a-5p, miR-194, miR-152, miR-128, miR-423, miR-92b, miR-139-3p, miR-667, miR-98, miR-181d, miR-500, miR-103, miR-99b*, miR-935, miR-674-5p, miR-743a, miR-352, miR-326, miR-181c, miR-504, miR-322*, miR-7a, miR-532-3p, miR-29a, miR-130b, miR-328, miR-345-5p, miR-29c, miR-215, miR-138*, miR-182, miR-147, miR-664, miR-339-5p, miR-743b, miR-96, miR-203, miR-130a, miR-346, miR-674-3p, miR-140*, miR-192, miR-409-3p, miR-106b*, let-7d, miR-28*, miR-219-2-3p, miR-148b-3p, miR-23b, miR-195, miR-30d, miR-301b, miR-320, miR-652, miR-322, miR-429, miR-291a-5p, miR-26a, miR-141, miR-185, miR-27b, miR-200c, miR-431, miR-16, miR-23a, miR-330*, miR-344-5p, miR-347, miR-125b*, miR-30b-5p, miR-218, miR-99a, miR-488, miR-493, miR-9*, miR-92a, miR-125b-5p, miR-183, miR-708, miR-191, miR-181b, miR-186, miR-872, miR-188, miR-22*, miR-27a, miR-7b, miR-598-3p, miR-490, miR-675, miR-10a-5p, miR-184, miR-100, miR-874, miR-200a, miR-30c, miR-99b, miR-212, let-7i, miR-30a, miR-199a-5p, miR-25, miR-99a*, miR-28, miR-30d*, miR-151*, miR-344-3p, miR-126*, miR-145, miR-20b-5p, miR-294, miR-489, miR-483, miR-132, miR-505, miR-7a*, let-7i*, miR-21*, miR-331, miR-434, miR-106b, miR-30e, miR-350, miR-34a, miR-219-1-3p, miR-543, miR-210, miR-30a*, miR-365, miR-378, miR-196b, miR-27a*, miR-361, miR-10b, miR-466c, miR-342-3p, miR-216a, miR-101a*, miR-24, miR-151, miR-205, miR-17-5p, miR-134, miR-296*, miR-26b*, miR-30e*, miR-382, miR-410, miR-327, miR-133b, miR-142-3p, miR-324-5p, miR-125a-3p, let-7d*, miR-19b, miR-223, miR-374, miR-127, miR-26b, miR-25*, miR-330, miR-146a, miR-295, miR-196a, miR-34b, miR-